keyword
MENU ▼
Read by QxMD icon Read
search

LDL HDL particle number

keyword
https://www.readbyqxmd.com/read/29463520/lipid-profile-and-effect-of-statin-treatment-in-pooled-phase-ii-and-phase-iii-baricitinib-studies
#1
Peter C Taylor, Joel M Kremer, Paul Emery, Steven H Zuckerman, Giacomo Ruotolo, Jinglin Zhong, Lei Chen, Sarah Witt, Chadi Saifan, Monika Kurzawa, James D Otvos, Margery A Connelly, William L Macias, Douglas E Schlichting, Terence P Rooney, Stephanie de Bono, Iain B McInnes
OBJECTIVES: Lipid profiles are altered by active disease in patients with rheumatoid arthritis (RA) and may be further modified by treatment with Janus kinase inhibitors and other disease-modifying antirheumatic drugs. METHODS: Lipid data were analysed from phase II and III studies of 4 mg (n=997) and 2 mg (n=479) oral baricitinib administered once daily in patients with moderate-to-severe active RA. Lipoprotein particle size and number and GlycA were evaluated with nuclear magnetic resonance in one phase III study...
February 20, 2018: Annals of the Rheumatic Diseases
https://www.readbyqxmd.com/read/29436756/alirocumab-versus-usual-lipid-lowering-care-as-add-on-to-statin-therapy-in-individuals-with-type-2-diabetes-and-mixed-dyslipidaemia-the-odyssey-dm-dyslipidemia-randomized-trial
#2
Kausik K Ray, Lawrence A Leiter, Dirk Müller-Wieland, Bertrand Cariou, Helen M Colhoun, Robert R Henry, Francisco J Tinahones, Maja Bujas-Bobanovic, Catherine Domenger, Alexia Letierce, Rita Samuel, Stefano Del Prato
AIMS: Individuals with type 2 diabetes (T2DM) and mixed dyslipidaemia represent a high-risk and difficult-to-treat population. ODYSSEY DM-DYSLIPIDEMIA (NCT02642159) compared alirocumab, a proprotein convertase subtilisin-kexin type 9 inhibitor, with usual care (UC) in individuals with T2DM and mixed dyslipidaemia not optimally managed by maximally-tolerated statins. MATERIALS AND METHODS: UC options (no additional lipid-lowering therapy; fenofibrate; ezetimibe; omega-3 fatty acid; nicotinic acid) were selected prior to stratified randomization to open-label alirocumab 75 mg every 2 weeks (Q2W; with increase to 150 mg Q2W at Week [W]12 if W8 non-high-density lipoprotein cholesterol [non-HDL-C] was ≥2...
February 13, 2018: Diabetes, Obesity & Metabolism
https://www.readbyqxmd.com/read/29382504/balanced-high-fat-diet-reduces-cardiovascular-risk-in-obese-women-although-changes-in-adipose-tissue-lipoproteins-and-insulin-resistance-differ-by-race
#3
K D Niswender, S Fazio, B A Gower, H J Silver
BACKGROUND: We previously reported that consuming a balanced high fat diet (BHFD) wherein total saturated fat was reduced and total unsaturated fat increased by proportionately balancing the type of fat (1/3 saturated, 1/3 monounsaturated, 1/3 polyunsaturated) led to significant improvements in inflammatory burden, blood pressure, and vascular function in obese premenopausal European American (EA) and African American (AA) women. OBJECTIVE: Here we compared changes in adipose tissue, lipoproteins, insulin resistance, and cardiovascular risk between EA and AA women...
January 27, 2018: Metabolism: Clinical and Experimental
https://www.readbyqxmd.com/read/29336935/update-on-the-laboratory-investigation-of-dyslipidemias
#4
REVIEW
I Ramasamy
The role of the clinical laboratory is evolving to provide more information to clinicians to assess cardiovascular disease (CVD) risk and target therapy more effectively. Current routine methods to measure LDL-cholesterol (LDL-C), the Friedewald calculation, ultracentrifugation, electrophoresis and homogeneous direct methods have established limitations. Studies suggest that LDL and HDL size or particle concentration are alternative methods to predict future CVD risk. At this time there is no consensus role for lipoprotein particle or subclasses in CVD risk assessment...
January 11, 2018: Clinica Chimica Acta; International Journal of Clinical Chemistry
https://www.readbyqxmd.com/read/29324459/discordance-between-lipoprotein-particle-number-and-cholesterol-content-an-update
#5
Eric P Cantey, John T Wilkins
PURPOSE OF REVIEW: The cholesterol content within atherogenic apolipoprotein-B (apoB) containing lipid particles is the center of consensus guidelines and clinicians' focus whenever evaluating a patient's risk for atherosclerotic cardiovascular disease. The pathobiology of atherosclerosis requires the retention of lipoprotein particles within the vascular intima over time followed by maladaptive inflammation resulting in plaque formation and rupture in some. The cholesterol content is widely variable within each particle creating either cholesterol-deplete or cholesterol-enriched particles...
January 10, 2018: Current Opinion in Endocrinology, Diabetes, and Obesity
https://www.readbyqxmd.com/read/29304079/particle-number-analysis-of-lipoprotein-subclasses-by-gel-permeation-hplc-in-patients-with-cholesteryl-ester-transfer-protein-deficiency
#6
Takeshi Okada, Tohru Ohama, Mitsuyo Okazaki, Kotaro Kanno, Hibiki Matsuda, Masami Sairyo, Yinghong Zhu, Ayami Saga, Takuya Kobayashi, Daisaku Masuda, Masahiro Koseki, Makoto Nishida, Yasushi Sakata, Shizuya Yamashita
OBJECTIVE: We previously reported that patients with cholesteryl ester transfer protein (CETP) deficiency (CETP-D) have a higher prevalence of atherosclerotic cardiovascular disease, in spite of increased HDL-C levels. However, characterization of HDL in CETP-D has not been well described. Therefore, we examined HDL particle number (PN) rather than HDL-C level. APPROACH AND RESULTS: Nine patients with CETP-D and 9 normolipidemic subjects were enrolled. We performed gel permeation high-performance liquid chromatography (GP-HPLC) analysis, determined the cholesterol and triglyceride composition of all lipoprotein subclasses, and calculated the PN of each subclass, which consisted of 3 VLDL (large, medium, and small), 4 LDL (large, medium, small, and very small), and 5 HDL (very large, large, medium, small, and very small) subclasses...
2018: PloS One
https://www.readbyqxmd.com/read/29241449/the-small-dense-ldl-particle-large-buoyant-ldl-particle-ratio-is-associated-with-glucose-metabolic-status-in-pregnancy
#7
Yanmin Chen, Mengkai Du, Jianyun Xu, Danqing Chen
BACKGROUND: The lipoprotein subfraction particle profile can be used to improve clinical assessments of cardiovascular disease risk and contribute to early detection of atherogenic dyslipidemia. Lipid alterations in gestational diabetes have been extensively studied, but the results have been inconsistent. Here, we investigated serum lipoprotein subfraction particle levels and their association with glucose metabolic status in pregnancy. METHODS: Twenty-eight pregnant women with gestational diabetes and 56 pregnant women with normal glucose tolerance matched for body mass index were enrolled in this study...
December 14, 2017: Lipids in Health and Disease
https://www.readbyqxmd.com/read/29226278/effects-of-multiple-freeze-thaw-cycles-on-measurements-of-potential-novel-biomarkers-associated-with-adverse-pregnancy-outcomes
#8
Sandra L Rebholz, John T Melchior, Jeffrey A Welge, Alan T Remaley, W Sean Davidson, Laura A Woollett
World-wide, millions of women enter preterm labor or have small newborns. Effective biomarkers are needed to identify women at risk for these adverse outcomes. A time and cost effective way to examine any potentially new biomarkers in samples collected during prior studies or trials that had been assayed for other metabolites would be highly useful. Thus, the current study aimed to determine if samples that had been previously thawed and re-frozen could be re-assayed for novel biomarkers, those being lipoprotein composition (sizing, proteome, lipids) and combined cholesterol and cytokine concentrations...
2017: Journal of Clinical and Laboratory Medicine
https://www.readbyqxmd.com/read/29221604/effect-of-evolocumab-on-lipoprotein-particles
#9
Peter P Toth, Naveed Sattar, Dirk J Blom, Seth S Martin, Steven R Jones, Maria Laura Monsalvo, Mary Elliott, Mike Davis, Ransi Somaratne, David Preiss
The level of low-density lipoprotein cholesterol (LDL-C) reflects the cholesterol carried mainly by low-density lipoprotein particles (LDL-P). LDL-C, however, does not always correlate with LDL-P because of the variable amounts of cholesterol per particle. Consideration of LDL-P concentrations in addition to LDL-C may help guide therapeutic decisions in a select number of patients. Evolocumab is a fully human monoclonal antibody directed against proprotein convertase subtilisin-kexin type 9 that lowers both LDL-C and cardiovascular events...
November 8, 2017: American Journal of Cardiology
https://www.readbyqxmd.com/read/29067238/lipid-disorders-in-patients-with-renal-failure-role-in-cardiovascular-events-and-progression-of-chronic-kidney-disease
#10
REVIEW
Luca Visconti, Salvatore Benvenga, Antonio Lacquaniti, Valeria Cernaro, Annamaria Bruzzese, Giovanni Conti, Michele Buemi, Domenico Santoro
The spectrum of lipid disorders in chronic kidney disease (CKD) is usually characterized by high triglycerides and reduced high dense lipoprotein (HDL), associated with normal or slightly reduced low dense lipoprotein (LDL)-cholesterol. This dyslipidemia is associated with an increased risk for atherosclerotic cardiovascular disease. Keys for the cardiovascular risk reduction in these patients are lowering the number and modifying the composition of the cholesterol-carrying atherogenic lipoprotein particles...
December 2016: Journal of Clinical & Translational Endocrinology
https://www.readbyqxmd.com/read/28829977/hdl-subclasses-and-the-common-cetp-taqib-variant-predict-the-incidence-of-microangiopatic-complications-in-type-2-diabetic-women-a-9years-follow-up-study
#11
Giuseppina T Russo, Annalisa Giandalia, Elisabetta L Romeo, Marco Muscianisi, Maria Concetta Ruffo, Angela Alibrandi, Alessandra Bitto, Fiorella Forte, Andrea Grillone, Bela Asztalos, Domenico Cucinotta
AIMS: Diabetic kidney disease (DKD) and retinopathy (DR) develop in a considerable number of subjects with Type 2 Diabetes (T2D) despite the achievement of the recommended targets for glycaemia and blood pressure. Atherogenic dyslipidemia may play a relevant role, especially in T2DM women. METHODS: We report our findings on the effect of diabetic dyslipidaemia, the HDL subclasses distribution and the common cholesteryl ester transfer protein (CETP)TaqIB variant on the incidence or the progression of DKD and DR in 97 T2D women, after a ∼9years of follow-up...
July 28, 2017: Diabetes Research and Clinical Practice
https://www.readbyqxmd.com/read/28826575/apolipoprotein-b-is-associated-with-carotid-atherosclerosis-progression-independent-of-individual-cholesterol-measures-in-a-9-year-prospective-study-of-multi-ethnic-study-of-atherosclerosis-participants
#12
Brian T Steffen, Weihua Guan, Alan T Remaley, James H Stein, Mathew C Tattersall, Joel Kaufman, Michael Y Tsai
BACKGROUND: High blood cholesterol contributes to atherosclerosis, yet reliance on the lipid panel alone may mischaracterize individuals with elevated lipoprotein particle numbers. OBJECTIVE: The aim of the article was to determine whether elevated lipoprotein or apolipoprotein measures are associated with carotid atherosclerosis and plaque progression independent of cardiovascular (CV) risk factors including standard lipids in a subcohort of 2228 Multi-Ethnic Study of Atherosclerosis participants...
September 2017: Journal of Clinical Lipidology
https://www.readbyqxmd.com/read/28826565/lipoprotein-particle-number-and-size-predict-vascular-structure-and-function-better-than-traditional-lipids-in-adolescents-and-young-adults
#13
Elaine M Urbina, Connie E McCoy, Zhiqian Gao, Philip R Khoury, Amy S Shah, Lawrence M Dolan, Thomas R Kimball
BACKGROUND: In adults, dyslipidemia is associated with higher carotid thickness and arterial stiffness, predictors of cardiovascular events. In young subjects, lipid concentrations have not been consistently associated with vascular measures. OBJECTIVE: The objective of the study was to compare nuclear magnetic resonance (NMR) measures of lipoprotein particle number (low-density lipoprotein [LDL] particle, low-density lipoprotein [HDL] particle, very low-density lipoprotein [VLDL] particle) and size (LDL size, HDL size, and VLDL size) to determine if they were associated with vascular measures more strongly than lipid concentrations (LDL cholesterol, HDL cholesterol, and triglyceride [TG])...
July 2017: Journal of Clinical Lipidology
https://www.readbyqxmd.com/read/28751001/effect-of-tofacitinib-on-lipid-levels-and-lipid-related-parameters-in-patients-with-moderate-to-severe-psoriasis
#14
Robert Wolk, Ehrin J Armstrong, Peter R Hansen, Bruce Thiers, Shuping Lan, Anna M Tallman, Mandeep Kaur, Svitlana Tatulych
BACKGROUND: Psoriasis is a systemic inflammatory disease associated with increased cardiovascular (CV) risk and altered lipid metabolism. Tofacitinib is an oral Janus kinase inhibitor. OBJECTIVE: The aim of the study was to investigate the effects of tofacitinib on traditional and nontraditional lipid parameters and CV risk markers in patients with psoriasis from a phase III study, OPT Pivotal 1. METHODS: Patients with psoriasis were randomized to tofacitinib 5 or 10 mg twice daily (BID) or placebo BID...
September 2017: Journal of Clinical Lipidology
https://www.readbyqxmd.com/read/28728064/ldl-subfractions-are-associated-with-incident-cardiovascular-disease-in-the-malm%C3%A3-prevention-project-study
#15
Dov Shiffman, Judy Z Louie, Michael P Caulfield, Peter M Nilsson, James J Devlin, Olle Melander
BACKGROUND AND AIMS: After assessing the risk for cardiovascular disease (CVD) based on traditional risk factors, decisions concerning lipid lowering therapy might remain uncertain. To investigate whether lipoprotein subfraction levels could aid these decisions, we assessed the association between lipoprotein subfractions and CVD, after adjustment for traditional risk factors including standard lipids. METHODS: Using a case-cohort design, participants were randomly drawn from the Malmö Prevention Project (MPP), a population-based prospective study of 18,240 participants, and supplemented with additional incident CVD events (5764 participants, 1784 CVD events)...
July 5, 2017: Atherosclerosis
https://www.readbyqxmd.com/read/28682864/characterization-of-lipid-profile-by-nuclear-magnetic-resonance-spectroscopy-1h-nmr-of-metabolically-healthy-obese-women-after-weight-loss-with-mediterranean-diet-and-physical-exercise
#16
Enrique Rodriguez-Garcia, Josefina Ruiz-Nava, Sonia Santamaria-Fernandez, Jose Carlos Fernandez-Garcia, Antonio Vargas-Candela, Raquel Yahyaoui, Francisco J Tinahones, Maria Rosa Bernal-Lopez, Ricardo Gomez-Huelgas
Obesity is associated with an atherogenic lipid profile. No data exists on lipoprotein particle profiles in metabolically healthy obese (MHO) individuals. Our aim is to characterize lipoprotein size, particle, and subclass concentrations in MHO women after 3 months of weight loss through dietary restriction and physical exercise.A total of 115 nondiabetic women (aged 35-55 years) with a body mass index (BMI) of 30 to 40 kg/m and ≤1 of the following criteria: blood pressure ≤135/85 mm Hg, fasting plasma glucose ≤100 mg/dL, HDL-cholesterol ≤50 mg/dL, and triglycerides ≤150 mg/dL were included...
July 2017: Medicine (Baltimore)
https://www.readbyqxmd.com/read/28554308/lipid-metabolism-in-patients-with-end-stage-renal-disease-a-five-year-follow-up-study
#17
Magdaléna Dušejovská, Barbora Staňková, Marek Vecka, Jana Rychlíková, Magdaléna Mokrejšová, Ivan Rychlík, Aleš Žák
BACKGROUND: Patients with end-stage renal disease (ESRD) exhibit high morbidity as well as mortality for atherosclerotic cardiovascular diseases (CVD). Therefore, we investigated differences in individual lipoprotein classes and subclasses in ESRD patients under chronic high volume hemodiafiltration (HV-HDF) in comparison with a control group. We also assessed the prognosis of these patients and analyzed these parameters after 5 years follow-up. METHODS: 57 patients and 50 controls were enrolled...
May 29, 2017: Current Vascular Pharmacology
https://www.readbyqxmd.com/read/28502513/relationship-between-noninvasive-scores-of-nonalcoholic-fatty-liver-disease-and-nuclear-magnetic-resonance-lipoprotein-abnormalities-a-focus-on-atherogenic-dyslipidemia
#18
Antonio J Amor, Montserrat Pinyol, Elsa Solà, Marta Catalan, Montserrat Cofán, Zoe Herreras, Nuria Amigó, Rosa Gilabert, Aleix Sala-Vila, Emilio Ros, Emilio Ortega
BACKGROUND: Nonalcoholic fatty liver disease (NAFLD) is an emerging, highly prevalent, cardiovascular risk factor, and lipoprotein proatherogenic disturbances likely explain a large part of this risk. However, information regarding associations between detailed nuclear magnetic resonance (NMR) lipoprotein changes and noninvasive NAFLD scores is lacking. OBJECTIVE: The objective of the study was to investigate the NMR-assessed atherogenic lipoprotein profile according to noninvasive NAFLD status...
March 2017: Journal of Clinical Lipidology
https://www.readbyqxmd.com/read/28460374/ldl-particle-number-and-size-and-cardiovascular-risk-anything-new-under-the-sun
#19
Janie Allaire, Cécile Vors, Patrick Couture, Benoît Lamarche
PURPOSE OF REVIEW: We provide here an up-to-date perspective on the potential use of LDL particle number and size as complementary risk factors to predict and manage cardiovascular disease (CVD) risk in the clinical realm. RECENT FINDINGS: Studies show that a significant proportion of the population has discordant LDL particle number and cholesterol indices [non-HDL cholesterol (HDL-C)]. Data also show that risk prediction may be improved when using information on LDL particle number in patients with discordant particle number and cholesterol data...
June 2017: Current Opinion in Lipidology
https://www.readbyqxmd.com/read/28450350/cholesterol-efflux-capacity-high-density-lipoprotein-particle-number-and-incident-cardiovascular-events-an-analysis-from-the-jupiter-trial-justification-for-the-use-of-statins-in-prevention-an-intervention-trial-evaluating-rosuvastatin
#20
RANDOMIZED CONTROLLED TRIAL
Amit V Khera, Olga V Demler, Steven J Adelman, Heidi L Collins, Robert J Glynn, Paul M Ridker, Daniel J Rader, Samia Mora
BACKGROUND: Recent failures of drugs that raised high-density lipoprotein (HDL) cholesterol levels to reduce cardiovascular events in clinical trials have led to increased interest in alternative indices of HDL quality, such as cholesterol efflux capacity, and HDL quantity, such as HDL particle number. However, no studies have directly compared these metrics in a contemporary population that includes potent statin therapy and low low-density lipoprotein cholesterol. METHODS: HDL cholesterol levels, apolipoprotein A-I, cholesterol efflux capacity, and HDL particle number were assessed at baseline and 12 months in a nested case-control study of the JUPITER trial (Justification for the Use of Statins in Prevention: An Intervention Trial Evaluating Rosuvastatin), a randomized primary prevention trial that compared rosuvastatin treatment to placebo in individuals with normal low-density lipoprotein cholesterol but increased C-reactive protein levels...
June 20, 2017: Circulation
keyword
keyword
114382
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"